5604-46-6

Basic information

• Product Name: 2-Amino-4,6-dichloro-5-formylpyrimidine
• Synonyms: 2-AMINO-4,6-DICHLORO-PYRIMIDINE-5-CARBALDEHYDE;2-AMINO-4,6-DICHLOROPYRIMIDINE-5-CARBOXALDEHYDE;2-AMINO-4,6-DICHLORO-5-FORMYL-PYRIMIDINE;2-AMINO-4,6-DICHLORO-5-PYRIMIDINECARBALDEHYDE;5-PYRIMIDINECARBOXALDEHYDE, 2-AMINO-4,6-DICHLORO-;2-AMINO-4,6-DICHLOROPYRIMIDINE-5-CARBOX&;2-amino-4,6-dichloro-5-pyrimid;2-azanyl-4,6-dichloro-pyrimidine-5-carbaldehyde
• CAS NO: 5604-46-6
• Molecular Formula: C₅H₃Cl₂N₃O
• Molecular Weight: 192
• EINECS: 1806241-263-5
• Product Categories: Pyridines, Pyrimidines, Purines and Pteredines;Aldehydes;Pyrazines, Pyrimidines & Pyridazines;Pyrimidine;Heterocycle intermediates;Pyrimidines;Pyrazines, Pyrimidines & Pyridazines;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;PyrimidinesHeterocyclic Building Blocks;Building Blocks;C1 to C6;C4 to C5;Carbonyl Compounds;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks;Organic Building Blocks;Heterocycle-Pyrimidine series
• Mol File: 5604-46-6.mol
• Article Data: 20

Chemical Properties

• Melting Point: 208-224 °C
• Boiling Point: 411.6 °C at 760 mmHg
• Flash Point: 202.7 °C
• Appearance: yellow solid
• Density: 1.688 g/cm³
• Vapor Pressure: 5.52E-07mmHg at 25°C
• Refractive Index: 1.684
• Storage Temp.: 2-8°C
• PKA: -1.57±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 2-Amino-4,6-dichloro-5-formylpyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4,6-dichloro-5-formylpyrimidine(5604-46-6)
• EPA Substance Registry System: 2-Amino-4,6-dichloro-5-formylpyrimidine(5604-46-6)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-36/37/38-43
• Safety Statements: 26-36/37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 5604-46-6(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Uses

Different sources of media describe the Uses of 5604-46-6 differently. You can refer to the following data:
1. Substrate used in the synthesis of an N-terminal surrogate in amino acid and peptide analogues.
2. 2-Amino-4,6-dichloro-pyrimidine-5-carbaldehyde is a substrate used in the synthesis of an N-terminal surrogate in amino acid and peptide analogues.

InChI:InChI=1/C5H3Cl2N3O/c6-3-2(1-11)4(7)10-5(8)9-3/h1H,(H2,8,9,10)

Upstream product

• 56-05-3 2-Amino-4,6-dichloropyrimidine 
• 56-09-7 2-amino-6-hydroxy-pyrimidin-4(3H)-one 
• 56-09-7 2-aminopyrimidine-4,6-diol 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 178392-67-1 2-amino-6-(N-benzyl-N-3-butynylamino)-4-chloro-5-formylpyrimidine 
• 871231-32-2 methyl 2-amino-4-chlorothieno[2,3-d]pyrimidine-6-carboxylate 
• 646511-92-4 [2-furan-2-yl-5-(3-phenyl-ureido)-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-acetic acid tert-butyl ester 
• 918658-04-5 benzyl 2-amino-4-pyrrolidinothieno[2,3-d]pyrimidine-6-carboxylate 
• 873544-84-4 2-amino-4-methoxy-thieno[2,3-d]pyrimidine-6-carboxylic acid (3,4,5-trimethoxy-phenyl)-amide 
• 873544-83-3 2-amino-4-methoxy-thieno[2,3-d]pyrimidine-6-carboxylic acid (4-methoxy-phenyl)-amide 
• 873544-80-0 2-amino-4-methoxythieno[2,3-d]pyrimidine-6-carboxylic acid 
• 873544-81-1 2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylic acid 
• 847560-46-7 2-amino-4-chloro-thieno[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 
• 162401-16-3 2-furan-2-yl-7H-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl amine 
• 377729-82-3 2-(5-amino-2-(furan-2-yl)-7H-pyrazole[4,3-e][1,2,4]triazole[1,5-c]pyrimidine-7-yl)ethyl 4-methylbenzenesulfonate 

Relevant articles and documents

Nitrogen-containing fused tricyclic derivative and application thereof

The invention discloses a nitrogen-containing fused tricyclic derivative and application thereof, and particularly relates to a novel nitrogen-containing fused tricyclic derivative and a pharmaceutical composition containing the nitrogen-containing fused tricyclic derivative, and the nitrogen-containing fused tricyclic derivative can be used as a selective adenosine A2A receptor antagonist. The invention also relates to a method for preparing the compound and the pharmaceutical composition and application of the compound and the pharmaceutical composition in preparation of drugs for treating adenosine A2A receptor related diseases, especially Parkinson's disease.

Development of pyrazolo[3,4-d]pyrimidine-6-amine-based TRAP1 inhibitors that demonstrate in vivo anticancer activity in mouse xenograft models

TNF Receptor Associated Protein 1 (TRAP1) is a mitochondrial paralog of Hsp90 related to the promotion of tumorigenesis in various cancers via maintaining mitochondrial integrity, reducing the production of reactive oxygen species, and reprogramming cellular metabolism. Consequently, Hsp90 and TRAP1 have been targeted to develop cancer therapeutics. Herein, we report a series of pyrazolo[3,4-d]pyrimidine derivatives that are mitochondria-permeable TRAP1 inhibitors. Structure-based drug design guided the optimization of potency, leading to the identification of compounds 47 and 48 as potent TRAP1 and Hsp90 inhibitors with good metabolic and plasma stability as well as acceptable CYP and hERG inhibition. X-ray co-crystallization studies confirmed both 47 and 48 interact with the ATP binding pocket in the TRAP1 protein. Compounds 47 and 48 demonstrated excellent anticancer efficiency in various cancer cells, with limited toxicity over normal hepatocyte and prostate cells. Mouse PC3 xenograft studies showed 47 and 48 significantly reduced tumor growth.

Fluorinated adenosine A2A receptor antagonists inspired by preladenant as potential cancer immunotherapeutics

Antagonism of the adenosine A2A receptor on T cells blocks the hypoxia-adenosinergic pathway to promote tumor rejection. Using an in vivo immunoassay based on the Concanavalin A mouse model, a series of A2A antagonists were studied and identified preladenant as a potent lead compound for development.Molecular modeling was employed to assist drug design and subsequent synthesis of analogs and those of tozadenant, including fluorinated polyethylene glycol PEGylated derivatives. The efficacy of the analogs was evaluated using two in vitro functional bioassays, and compound 29, a fluorinated triethylene glycol derivative of preladenant, was confirmed as a potential immunotherapeutic agent.